Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 10/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 9/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7159196 | 0.81 | ALDH1A1 (0.37) | ALDH1A1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL2669375 | 0.78 | ALDH1A1 (0.35) | ALDH1A1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL658257 | 0.78 | CYP4F2 (0.47) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5520484 | 0.78 | ALDH1A1 (0.40) | ALDH1A1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL645688 | 0.77 | KDM4E (0.55) | ALDH1A1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL31407736 | 0.77 | KDM4E (0.55) | ALDH1A1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL27956784 | 0.76 | GPR119 (0.38) | ALDH1A1GABRG2GABRB3GABRA1GABRA3 | |
| Hydrochloric Acid SCHEMBL27420852 | 0.76 | ALDH1A1 (0.39) | ALDH1A1GABRG2GABRB3GABRA1GABRA3 | |
| SCHEMBL361254 | 0.74 | AAK1 (0.45) | GABRG2GABRB3GABRA1GABRA3GABRA2 | |
| SCHEMBL18044633 | 0.74 | AAK1 (0.38) | ALDH1A1GABRG2GABRB3GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4647431-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Gan & lee Pharm Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20250002489-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024215820-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC | 2024-08-29 | — | — | US | disclosed |
| EP-4419520-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | ALDH1A1 1370/4885GABRG2 3289/4885GABRB3 2966/4885 |
| US-20250002489-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | ADRM1, PSMD7, UBQLN2 | ALDH1A1 3007/4885GABRG2 3682/4885GABRB3 3781/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | ALDH1A1 2057/4885GABRG2 1001/4885GABRB3 1603/4885 |
| US-20240287138-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | TNF, TNFRSF1A, CD40 | ALDH1A1 3774/4885GABRG2 2560/4885GABRB3 3105/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | ALDH1A1 1370/4885GABRG2 3289/4885GABRB3 2966/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | ALDH1A1 4472/4885GABRG2 1548/4885GABRB3 1550/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | ALDH1A1 2057/4885GABRG2 1001/4885GABRB3 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.